Medicine
Susvimo 100 mg/1 mL injection
Susvimo 100 mg/1 mL injection is a prescription medicine containing Ranibizumab for intravitreal use, marketed by Genentech, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store SUSVIMO initial fill needle kit at 2°C to 8°C (36°F to 46°F). Do not…
Key facts
- Active ingredient (INN)
- Ranibizumab
- Brand
- Susvimo
- Strength
- 100 mg/1 mL
- Dosage form
- Injection
- Route
- Intravitreal
- Packs
- 1 vial of 1 mL
- Marketing authorisation holder
- Genentech
- Manufacturer
- Genentech
- Origin register
- US FDA, United States
- Storage
- Store SUSVIMO initial fill needle kit at 2°C to 8°C (36°F to 46°F). Do not freeze. Store SUSVIMO (ranibizumab injection) 100 mg/ mL vial at 2°C to 8°C (36°F to 46°F). Do not freeze. Prior to use, the unopened vial may be kept at 9°C to 30°C (48°F to 86°F) for up to 24 hours provided it is protected from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- S01LA04 Bevacizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 October 2021
- Identifiers
- RxCUI 2584857, 2584863DailyMed set ID 9c6d9e2a-9a77-4d11-b692-de87cfde3444NDC 50242-078Application BLA761197
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ranibizumab
Clinical summary
Ranibizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of patients with lUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with, among other approved uses. MedsAcross supplies Ranibizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RanibizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LUCENTIS prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- Lucentis: European public assessment report (EPAR) · European Medicines Agency
- Susvimo: European public assessment report (EPAR) · European Medicines Agency
Need Susvimo 100 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.